SUMMARY In a double blind randomised trial, we found no evidence that nebulised ipratropium bromide was of clinical benefit in acute bronchiolitis.
No pharmacological agent has been shown to alter the natural history of acute viral bronchiolitis.12 Furthermore lung function studies have failed to show any objective benefit from salbutamol, orciprenaline, phenylephrine, adrenaline, and isoprenaline.3-5 We recently6 confirmed the ineffectiveness of salbutamol but found that the anticholinergic agent ipratropium bromide led to a reduction in work of breathing in 6 of 15 infants with severe bronchiolitis. This present study was designed to assess the clinical benefit of ipratropium bromide in the treatment of acute viral bronchiolitis.
Patients and methods
Sixty six children who had been admitted to hospital with acute bronchiolitis were included in the study. The diagnosis of bronchiolitis was based on the typical clinical features of a tight, irritating cough, breathlessness, respiratory distress, hyperinflation, fine crepitations, and expiratory rhonci. Respiratory syncytial virus (RSV) was isolated from 45 (68%) of the children. Their average age was 130 days (range 49-368 days), 40 were boys and 26 girls.
In a randomised, double blind fashion, the children received 6 hourly nebulised solutions containing 250 ,g of ipratropium bromide in 2 ml of saline (34 patients) or normal saline alone (32 patients). Treatment was stopped when the respiratory signs had resolved sufficiently for discharge home.
One of us made daily measurements of pulse and respiratory rate together with assessments of cough, rhinitis, nasal flaring, cyanosis, hyperinflation, tracheal tug, intercostal recession, subcostal recession, respiratory distress, crepitations, and rhonchi, using a four point scale scoring system for each parameter. Another of us obtained detailed information from parents and nursing staff about whether there was an immediate response to each nebulised treatment.
Results
The background information and clinical findings on admission to the trial were similar in the two treatment groups, with no important differences observed in any parameters. We found no evidence that ipratropium bromide altered the rate of resolution of bronchiolitis. As shown in Table 1 , the number of treatments needed in each group was similar. The daily assessments reflected the clinical improvement with time. The ipratropium bromide treated group did not recover more quickly than the placebo group. Two children who received ipratropium bromide developed a tachycardia and persistent coughing with treatment, and it seems likely that treatment prolonged their illness.
Information was available from the parents of 42 children about immediate response to treatment. Based on parental assessments, 11 of 24 children treated with ipratropium bromide were helped compared with only 3 of 18 who received a placebo (X2 = 2.73, P<O-1). When we combined the opinions of the parents and nursing staff, however, the two treatment groups were very similar ( Table 2) . 
Discussion
This clinical trial does not support the widespread introduction of ipratropium bromide in acute bronchiolitis. Furthermore, we were unable to identify a subgroup of children (such as those with a family history of asthma) who were more likely to respond to the drug than to placebo. Our measurements were sensitive to change and we found appreciable improvements in clinical parameters when comparing the serial daily assessments. We also observed that the pulse rate fell more quickly in the placebo treated group than in the ipratropium bromide group, suggesting that the drug was being absorbed. It seems likely that our inability to show a significant benefit of ipratropium bromide over placebo, or indeed any clear trends for benefit, is a valid finding. This study provides further evidence for the ineffectiveness of bronchodilator treatment in acute bronchiolitis. 
